Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit

Rhea-AI Summary

Whitehawk Therapeutics (Nasdaq: WHWK) announced that President and CEO Dave Lennon, PhD, will join a virtual fireside chat at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA on Wednesday, May 27, 2026, at 11:00 AM ET.

A live webcast and 30-day replay will be available via the company’s investor relations website.

News Market Reaction – WHWK

+3.69%

+3.69% Session close to close

In the May 20 session, WHWK gained 3.69%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights additional investor visibility for Whitehawk’s ADC platform via a TD Co...

Analysis

This announcement highlights additional investor visibility for Whitehawk’s ADC platform via a TD Cowen oncology summit fireside chat on May 27, 2026. Recent history includes a sizeable $87.5M private placement, Q1 2026 results showing a $22.2M net loss but cash into 2028, and positive AACR 2026 preclinical data. Repeated conference appearances have sometimes coincided with share weakness, so subsequent pipeline updates and financing use-of-proceeds remained key metrics to track.

Key Figures

Conference edition: 7th Annual Event date: May 27, 2026 Event time: 11:00 AM ET +5 more

8 metrics

Conference edition 7th Annual TD Cowen Oncology Innovation Summit

Event date May 27, 2026 Scheduled fireside chat at TD Cowen summit

Event time 11:00 AM ET Start time for virtual fireside chat

Webcast replay period 30 days Replay availability after event

Current price $4.07 Prior to news release

Daily change -4.24% 24h price change before article

52-week range $1.57–$5.495 52-week low and high

200-day MA $2.74 Technical trend indicator, price trading above

Historical Context

5 past events · Latest: May 15 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 15	Conference participation	Positive	-7.8%	Announcement of Stifel virtual targeted oncology forum fireside chat.
May 13	Private placement	Positive	+25.8%	Approximately $87.5M private placement to fund ADC pipeline and operations.
May 07	Earnings and pipeline	Negative	-5.1%	Q1 2026 loss, higher R&D, no revenue, but strong cash runway into 2028.
Apr 19	Preclinical data	Positive	+2.9%	AACR 2026 preclinical ADC data showing tumor regressions and tolerability.
Apr 16	Conference participation	Positive	-2.8%	Jones Trading Post-AACR fireside chat with webcast access and replay.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows positive reactions to financing and strong ADC data, but negative reactions to routine events like earnings and conference participation, indicating sensitivity to perceived dilution and fundamental updates over visibility-only news.

Recent Company History

Over the past months, Whitehawk reported Q1 2026 results with cash of $123.0M and no revenue, continued Phase 1 ADC trials, and planned an IND for HWK-206 in mid-2026. A private placement announced on May 13, 2026 to raise about $87.5M drove a 25.77% gain, while preclinical AACR 2026 ADC data yielded a smaller 2.92% rise. In contrast, multiple fireside chat and forum participation announcements on April 16 and May 15 saw modest declines, similar in nature to today’s conference-focused news.

Key Terms

antibody drug conjugate, adc

2 terms

antibody drug conjugate medical

"to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments"

An antibody drug conjugate is a targeted medical treatment that combines a special antibody with a powerful drug, allowing precise delivery of the medicine directly to cancer cells or other harmful cells in the body. For investors, it represents a sophisticated approach to therapy that could improve treatment effectiveness and reduce side effects, potentially leading to significant growth opportunities in the biotech and pharmaceutical sectors.

adc medical

"to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments"

An antibody-drug conjugate (ADC) is a targeted cancer medicine that pairs an antibody that recognizes specific markers on tumor cells with a potent cell-killing drug, connected so the toxic payload is delivered directly to the cancer. For investors, ADCs matter because successful ADCs can improve patient outcomes and reduce side effects compared with traditional chemotherapy, shaping clinical trial success, regulatory approval chances, commercial demand, and a company’s valuation much like a guided missile versus a general bomb.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MORRISTOWN, N.J., May 20, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced Dave Lennon, PhD, President and CEO, will participate in a virtual fireside chat as part of the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA on Wednesday, May 27, 2026, at 11:00 AM ET.

A live webcast of the event can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the event.

About Whitehawk Therapeutics 
Whitehawk Therapeutics is a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk's advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement. More information on the Company is available at www.whitehawktx.com and connect with us on LinkedIn.

Contact:
IR@whitehawktx.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/whitehawk-therapeutics-to-participate-in-the-td-cowen-7th-annual-oncology-innovation-summit-302777476.html

SOURCE Whitehawk Therapeutics, Inc.

FAQ

When will Whitehawk Therapeutics (WHWK) present at the TD Cowen 7th Annual Oncology Innovation Summit?

Whitehawk Therapeutics will participate in a virtual fireside chat on Wednesday, May 27, 2026, at 11:00 AM ET. According to the company, this session is part of the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA.

How can investors access the Whitehawk Therapeutics (WHWK) webcast for the TD Cowen Oncology Innovation Summit?

Investors can access a live webcast of the fireside chat by visiting the Whitehawk Therapeutics investor relations website. According to the company, the replay will remain available for approximately 30 days following the event.

Who will represent Whitehawk Therapeutics (WHWK) at the TD Cowen Oncology Innovation Summit on May 27, 2026?

Whitehawk Therapeutics will be represented by Dave Lennon, PhD, President and CEO, in a virtual fireside chat. According to the company, his participation highlights its focus as a clinical-stage oncology therapeutics company developing ADC cancer treatments.

What is the focus of Whitehawk Therapeutics (WHWK) as it participates in the TD Cowen Oncology Innovation Summit?

Whitehawk Therapeutics is a clinical-stage oncology therapeutics company developing improved antibody drug conjugate (ADC) cancer treatments. According to the company, it applies advanced technologies to established tumor biology to efficiently deliver these ADC therapies.